Lab-Grown 3D tumors could personalize blood cancer treatment
NCT ID NCT03890614
First seen Feb 27, 2026 · Last updated Jun 19, 2026 · Updated 22 times
Summary
This study creates 3D organoids from bone marrow samples of 70 people with blood cancers to test how well different chemotherapy combinations kill cancer cells. The goal is to see if these lab models can predict which treatment works best for each patient, especially when the cancer returns. Researchers will also study how cancer cells interact with their surroundings to better understand the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this platform could help doctors choose the most effective chemotherapy for individual patients with relapsed blood cancers.
What could go wrong
This is an early-stage, observational study using lab-grown models, not a direct treatment trial. The approach may not translate to real patient outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.